HC Wainwright Reaffirms “Buy” Rating for Telix Pharmaceuticals (NASDAQ:TLX)

Telix Pharmaceuticals (NASDAQ:TLX)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a research report issued on Tuesday,Benzinga reports. They presently have a $20.00 price target on the stock. HC Wainwright’s price target points to a potential upside of 120.02% from the stock’s current price.

Other equities research analysts also recently issued reports about the company. Weiss Ratings reiterated a “sell (d)” rating on shares of Telix Pharmaceuticals in a report on Wednesday, January 21st. Royal Bank Of Canada upgraded Telix Pharmaceuticals from a “hold” rating to a “moderate buy” rating in a report on Monday, January 19th. Wall Street Zen downgraded Telix Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Sunday, March 15th. Finally, Citigroup lifted their price objective on Telix Pharmaceuticals from $22.00 to $22.50 and gave the stock a “buy” rating in a report on Tuesday, February 24th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $21.13.

Telix Pharmaceuticals Trading Down 0.4%

TLX opened at $9.09 on Tuesday. The stock has a 50-day moving average price of $7.73 and a 200-day moving average price of $8.72. The company has a quick ratio of 1.27, a current ratio of 1.43 and a debt-to-equity ratio of 1.08. Telix Pharmaceuticals has a 1 year low of $6.28 and a 1 year high of $20.00.

Telix Pharmaceuticals (NASDAQ:TLX) last posted its quarterly earnings results on Friday, February 20th. The company reported ($0.01) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.05 by ($0.06). The firm had revenue of $206.72 million during the quarter, compared to analysts’ expectations of $421.50 million. On average, equities research analysts anticipate that Telix Pharmaceuticals will post 0.24 EPS for the current fiscal year.

Institutional Investors Weigh In On Telix Pharmaceuticals

A number of large investors have recently made changes to their positions in the company. Portland Investment Counsel Inc. grew its stake in shares of Telix Pharmaceuticals by 108.0% during the 4th quarter. Portland Investment Counsel Inc. now owns 266,200 shares of the company’s stock valued at $2,063,000 after purchasing an additional 138,200 shares during the period. Lazard Asset Management LLC grew its stake in shares of Telix Pharmaceuticals by 118.6% during the 4th quarter. Lazard Asset Management LLC now owns 250,517 shares of the company’s stock valued at $1,876,000 after purchasing an additional 135,893 shares during the period. Millennium Management LLC bought a new stake in shares of Telix Pharmaceuticals during the 3rd quarter valued at about $1,883,000. Russell Investments Group Ltd. bought a new stake in shares of Telix Pharmaceuticals during the 2nd quarter valued at about $975,000. Finally, Private Advisor Group LLC grew its stake in shares of Telix Pharmaceuticals by 67.3% during the 3rd quarter. Private Advisor Group LLC now owns 42,112 shares of the company’s stock valued at $403,000 after purchasing an additional 16,945 shares during the period.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.